Abstract. NQ12, an antithrombotic agent, has been reported to display a potent antiplatelet activity. This study was undertaken to reveal the effect of NQ12 on rabbit platelet aggregation and signal transduction involved in the arachidonic acid (AA) cascade. NQ12 concentrationdependently suppressed collagen-, AA-, and U46619-induced rabbit platelet aggregation, with IC 50 values of 0.71 ± 0.2, 0.82 ± 0.3, and 0.45 ± 0.1 µM, respectively. In addition, the concentration-response curve of U46619 was shifted to the right after NQ12 treatment, indicating an antagonism on thromboxane (TX) A 2 receptors. The collagen-stimulated AA liberation was inhibited by NQ12 in the same pattern as its inhibition of platelet aggregation. Further study revealed that NQ12 potently suppressed AA-mediated TXA 2 formation, but had no effect on the PGD 2 production, indicating an inhibitory effect on TXA 2 synthase, which was supported by a TXA 2 synthase activity assay indicating that NQ12 concentration-dependently inhibited TXA 2 formation converted from PGH 2 . On the other hand, the AA-stimulated 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) formation was also suppressed by NQ12. Taken together, these results suggest that NQ12 has a potential to inhibit TXA 2 synthase activity and TXA 2 receptors, and it can modulate AA liberation as well as 12-HETE formation in platelets. This may be a convincing mechanism for the antithrombotic action of NQ12.
Introduction
Platelet activation plays a central role in hemostasis, but also contributes to thrombosis in arterial circulation, the primary cause of heart attacks and strokes. Once injury occurs in the vessel wall, platelets first become arrested on the exposed subendothelial surface and become activated. Thromboxane (TX) A 2 acts as a potent agonist and potentiator of platelet aggregation, which affects other platelets and causes them to change shape, extend pseudopods, and adhere to platelets on the damaged surface; regulates vascular tone; and makes a major contribution to the formation of some thrombi (1 -4) . In platelets, TXA 2 is mainly produced via cyclooxygenase (COX)-TXA 2 synthase from arachidonic acid (AA), which is increased dramatically via action of phospholipase (PL) C and PLA 2 -mediated phospholipid hydrolysis, when platelets are activated by various inducers (5 -9) . On the other hand, 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE), a parallel metabolite of AA via 12-lipoxygenase (12-LOX), has also been reported to act as a platelet activator to promote thrombus formation in vivo (10, 11) and gives rise to platelet aggregation and aortic smooth muscle cell migration in vitro (12 -14) . It seems likely that 12-HETE as well as TXA 2 is involved in the initiation and propagation of thrombotic and atherosclerotic disorders. Drugs that have inhibitory effects on TXA 2 production as well as membrane TXA 2 receptor or 12-HETE formation may be beneficial for the patients with cardiovascular diseases.
It has been reported that 1,4-naphthoquinone derivatives exhibited various pharmacological effects such as antiviral, antifungal, anticancer, and antiplatelet activities (15, 16) . Previously, we found that NQ12, a synthetic 1,4-naphthoquinone derivative, showed a potent preventive effect on animal pulmonary thrombosis, which may be mediated by inhibition of platelet aggregation rather than that of coagulation (16) . In addition, even though the antiplatelet activity of NQ12 was revealed to be mediated by the inhibition of phosphoinositide breakdown (16) , the precise effect of NQ12 on the AA cascade remains unknown.
In the present study, we investigated the effect of NQ12 on the AA cascade by measuring AA liberation and formations of TXB 2 , prostaglandin (PG) D 2 , and 12-HETE from exogenous AA in rabbit platelets. In addition, the antagonistic effect of NQ12 on TXA 2 receptors and the possible inhibitory effect on TXA 2 synthase activity were also examined.
Materials and Methods

Materials
NQ12, 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4-naphthoquinone ( Fig. 1) , was synthesized and characterized as previously described (16) . AA and collagen were purchased from Chrono-Log Co. (PA, USA). U46619 (9,11-dideoxy-9α,11α-methanoepoxyprostaglandin F 2α ), 12-HETE, PGD 2 , and PGH 2 were from Cayman Chemical (Ann Arbor, MI, USA). 
Animals
New Zealand white rabbits were purchased from Sam-Tako Animal Co. (Osan, Korea) and acclimatized for 1 week at 24°C and 55% humidity, with free access to a commercial pellet diet obtained from Samyang Co.
(Wonju, Korea) and drinking water before experiments. The animal studies have been carried out in accordance with the Guide for the Care and Use of Laboratory Animals, Chungbuk National University, Korea.
Washed rabbit platelet preparation
Washed rabbit platelets were prepared as Jin et al. described (17) . In brief, platelet-rich plasma was obtained from rabbit blood, anticoagulated with a onetenth volume of 1% EDTA, by centrifugation at 230 × g for 10 min. Platelets were sedimented by centrifugation of the platelet-rich plasma at 800 × g for 15 min and then washed twice with Hepes buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 2.9 mM NaH 2 PO 4 , 5.6 mM glucose, 0.35% BSA, and 3.8 mM Hepes, pH 6.5) containing 0.4 mM EGTA. The washed platelets were resuspended in Hepes buffer (pH 7.4).
Platelet aggregation assay in vitro
Platelet aggregation was measured by using an aggregometer (Chrono-Log Co., Havertown, PA, USA) according to the turbidimetry method of Born (18) . Briefly, washed rabbit platelet suspension was incubated at 37°C for 4 min in the aggregometer with stirring at 1000 rpm before aggregation was induced by addition of collagen (10 µg/ ml), AA (100 µM), or U46619 (1 µM). To investigate the antagonism of NQ12 on U46619-induced platelet aggregation, the concentration-response relationship was determined in the absence or presence of a range of NQ12 concentrations; for these experiments, aspirin-treated platelets (50 µM for 5 min) were used to prevent any possible contribution of endogenous AA metabolites to platelet aggregation. The resulting aggregation, measured as the change in light transmission, was recorded for 5 min. The extent of platelet aggregation is expressed as % of the control (maximum platelet aggregation induced by respective agonist).
Measurement of TXB 2 , PGD 2 and 12-HETE generations
The TXB 2 , PGD 2 , and 12-HETE generations were measured as Sato et al. described (19) . In brief, washed rabbit platelets (4 × 10 8 cells / ml) were preincubated with various concentrations of NQ12 or aspirin (50 µM, a specific COX inhibitor) at 37°C for 3 min and then further incubated with a mixture of [
3 H]AA and unlabeled AA (2 µM, 1 µCi / ml) for 5 min. The reaction was terminated by addition of stop solution (2.6 mM EGTA, 130 µM BW755C). Lipids were extracted and separated by TLC on silica gel G plates with the following development system: ethyl acetate / isooctane / acetic acid / H 2 O (11/ 5/ 2 / 10, v/ v / v / v). The area corresponding to each lipid was scraped off and the radioactivity was determined by liquid scintillation counting.
TXA 2 synthase activity assay
The TXA 2 synthase activity was assayed as Chang et al. described (20) . In brief, aliquots of PGH 2 , in anhydrous acetone, were pipetted into glass tubes. The acetone was evaporated under a gentle stream of nitrogen, and PGH 2 was redissolved immediately in ethanol. Platelet suspensions were incubated with the samples at 37°C for 3 min prior to addition of 5 µM PGH 2 . The final concentration of ethanol was 0.1% (v / v). At 5 min after addition of PGH 2 , the incubations were terminated by addition of cooling EDTA (2 mM) and centrifuged at 1500 × g at 4°C for 4 min. TXB 2 level in the supernatant was determined by an enzymeimmunoassay kit. TXA 2 synthase activity is reflected by the production of TXB 2 .
Measurements of AA and diacylglycerol (DAG) formation
The AA and DAG formations were measured as Akiba et al. described (5) . In brief, platelet-rich plasma was preincubated with [
3 H]AA (1 µCi / ml) at 37°C for 1.5 h and then washed as described above. The [
8 cells / ml) were pretreated with 100 µM BW755C, a COX and LOX inhibitor, and various concentrations of NQ12 or U73122 (10 µM, a PLC inhibitor used as the positive control) at 37°C for 3 min in the presence of 1 mM CaCl 2 and then stimulated with collagen (10 µg / ml). The reaction was terminated by addition of chloroform / methanol/ HCl (200 / 200/ 1, v / v/ v). Lipids were extracted and separated by TLC on silica gel G plates with the following development system: petroleum ether / diethyl ether / acetic acid (40 / 40/ 1, v / v/ v). The area corresponding to AA or DAG was scraped off and the radioactivity was determined by liquid scintillation counting.
Assay of cytosolic PLA 2 (cPLA 2 ) activity Purified pig spleen cytosolic PLA, was provided by Dr. D.K. Kim (College of Pharmacy, Chung Ang University, Seoul, Korea). The cPLA 2 activity was assayed using sonicated liposomes, prepared as described by Chang et al. (20) . The standard PLA, assay buffer (200 µL) contained 75 mM Tris-HCl (pH 9.0), 5 mM CaCl 2 , 1 mg / mL fatty acid free BSA, and 0.47 nmol of l-acyl-2-[
14 C]AA-GPE. After preincubating the test compounds with PLA 2 at 37°C for 10 min, the reaction was allowed to continue for 30 min. Then the reaction was terminated by adding 1.25 mL of Dole's reagent (78% propan-2-ol, 20% n-heptane, and 2% 2 M aqueous H 2 SO 4 ); and the liberated [ 14 C]AA was extracted as follows: 0.55 mL of water was added and the sample was vortexed and then centrifuged at 1200 × g for 5 min. Then 0.75 mL of the upper phase was transferred to a new tube that contained 100 mg of silica gel and 0.75 mL of n-heptane. The sample was vortex-mixed and centrifuged for an additional 5 min each, after which 1.4 mL of supernatant was removed for scintillation counting.
Statistical analyses
The experimental results were each expressed as the mean ± S.E.M. A one-way analysis of variance (ANOVA) was used for multiple comparison (Sigma Stat ® ; Jandel Co., San Rafael, CA, USA). If there was a significant variation between treated-groups, Dunnett's test was applied. The data were considered significant with a probability less than 0.05.
Results
Effect of NQ12 on rabbit platelet aggregation in vitro
As shown in Fig. 2 , NQ12 potently inhibited collagen-, AA-, and U46619-induced rabbit platelet aggregation in a concentration-dependent manner, with IC 50 values of 0.71 ± 0.2, 0.82 ± 0.3, and 0.45 ± 0.1 µM, respectively.
Effect of NQ12 on conversion of AA to TXB 2 , PGD 2 , and 12-HETE As shown in Fig. 3A , NQ12 concentration-dependently suppressed TXB 2 generation induced by addition Fig. 2 . Effect of NQ12 on washed rabbit platelet aggregation. Washed rabbit platelet suspension was incubated at 37°C in an aggregometer with stirring at 1000 rpm, and then NQ12 was added. After 3-min preincubation, the platelet aggregation was induced by addition of AA (100 µM), collagen (10 µg/ mL), or U46619 (1 µM). The aggregation percents were presented as % of maximal aggregation induced by the respective inducers. Data are expressed as the mean ± S.E.M. (n = 4). Significantly different from corresponding the control at *P<0.05, **P<0.01.
of [
3 H]AA in intact rabbit platelets. The TXB 2 formation was inhibited by 4.3%, 26.5%, 43.3%, and 57.8% at the concentrations of 0.1, 0.5, 1.0, and 3.0 µM, respectively. NQ12, however, had no effect on PGD 2 generation (Fig. 3B) . These results suggest that NQ12 may selectively inhibit the activity of TXA 2 synthase rather than that of COX because TXA 2 and PGD 2 are simultaneously produced by AA through the COX pathway. In addition, NQ12 also suppressed 12-HETE production by 3.8%, 12.3%, 40.5%, and 48.2% at the concentrations of 0.1, 0.5, 1.0, and 3.0 µM, respectively (Fig. 3C) . Aspirin, a specific COX inhibitor used as a positive control, completely blocked COX-mediated TXA 2 and PGD 2 productions at a concentration of 50 µM, while it increased 12-HETE formation.
Effect of NQ12 on TXA 2 synthase activity
The conversion of AA to TXA 2 in platelets requires the action of two enzymes, COX and TXA 2 synthase. TXA 2 synthase catalyzes the conversion of PGH 2 to TXA 2 in platelets. By utilizing PGH 2 , it is possible to circumvent the COX step during AA metabolism. The addition of increasing concentrations of PGH 2 to rabbit platelet suspensions produced a concentration-dependent increase of TXB 2 (data not shown). Thus, rabbit platelet suspensions containing PGH 2 are adequate for the direct evaluation of the TXA 2 synthase inhibitor. In washed rabbit platelet suspensions, the level of TXB 2 in unstimulated platelets was about 7.5 ng / 4 × 10 8 platelets. After incubation of platelet suspensions with PGH 2 (5 µM) at 37°C for 5 min, TXB 2 formation was 334.0 ng / 4 × 10 8 platelets. NQ12 concentration-dependently inhibited the conversion of PGH 2 into TXB 2 in Fig. 3 . Effect of NQ12 on conversion of arachidonic acid to TXB2, PGD2, and 12-HETE and TXA2 synthase activity in rabbit platelets. Washed rabbit platelets were preincubated with various concentrations of NQ12 for 3 min and then further incubated with a mixture of [ 
H]TXB2 (A), [
3 H]PGD2 (B), and [ 3 H]12-HETE (C) generations were measured as described under Materials and Methods. TXA2 synthase activity assay (D): After the rabbit platelets were preincubated with indomethacin (20 µM) at 37°C for 2 min, the platelet suspensions containing DMSO (0.1%), NQ12, or imidazole (500 µM) were further incubated for 3 min and then 5 µM PGH2 was added. At 5 min after addition of PGH2, the incubations were terminated by addition of cooling EDTA (2 mM) and centrifuged at 12,000 × g at 4°C for 4 min. TXB2 level in the supernatants was determined by an enzyme immunoassay kit. TXA2 synthase activity is reflected by the production of TXB2, which is presented as the mean ± S.E.M. (n = 3). Significantly different from the corresponding control at *P<0.05, **P<0.01. platelets (Fig. 3D) , with the inhibition percentages of 3.0%, 21.1%, 46.7%, and 56.1% at the concentrations of 0.1, 0.5, 1.0, and 3.0 µM, respectively. Similarly, imidazole (50 µM, a typical TXA 2 synthase inhibitor) also potently inhibited TXB 2 formation.
Effect of NQ12 on U46619-induced rabbit platelet aggregation
When preincubated with rabbit platelets for 3 min, NQ12 concentration-dependently reduced platelet aggregation elicited by various concentrations of U46619 under COX blockade with aspirin (50 µM). At the concentrations of 0.5 and 1.0 µM, NQ12 produced a shift to the right of the U46619-induced concentrationresponse curve, indicating an antagonistic effect on TXA 2 receptors. Similarly, the IC 50 values of NQ12 for inhibition of the maximal extent of platelet aggregation induced by U46619 increased with augmenting concentrations of agonist (Fig. 4) .
Effect of NQ12 on collagen-induced AA and DAG formation as well as cPLA 2 activity Figure 5A shows that pretreatment of NQ12 concentration-dependently inhibited collagen-induced AA liberation from [ Fig. 4 . Effect of NQ12 on U46619-induced rabbit platelet aggregation. Aspirin-treated rabbit platelets (50 µM aspirin for 5 min) were used to prevent any possible contribution of endogenous AA metabolites to platelet aggregation. Rabbit platelets were incubated with NQ12 or DMSO (0.1%) at 37°C for 4 min, and then U46619 was added to trigger aggregation. The peak level of aggregation was measured 4 min after the addition of stimulator. The percent aggregation was calculated assuming the maximal value of the control produced by U46619 (1 µM) to be 100%. Each data point is expressed as the mean ± S.E.M. (n = 3). (Fig. 5B) . U73122 (50 µM), a positive control, also completely inhibited AA and DAG formation. The effect of NQ12 on cPLA 2 activity, a rate-limited enzyme in AA generation, was examined in purified 100-kDa cPLA 2 from pig spleen. AACOCF3, a direct inhibitor of cPLA 2 , inhibited the hydrolysis of 2-[
14 C]AA-GPE by approximately 59% at 50 µM (Fig. 5B) . However, NQ12 had no effect on PLA 2 activity at the concentration at which it inhibited collagen-induced AA release. Therefore, the inhibition of AA liberation by NQ12 may be due to its inhibition of phosphoinositide breakdown rather than a direct inhibition of cPLA 2 activity because it has been reported that inhibition of phosphoinositide breakdown was able to block the AA liberation completely (21) .
Discussion
In the present study, we investigated the effects of NQ12, an antithrombotic agent, on rabbit platelet aggregation and signal transduction involved in the AA cascade. NQ12 potently inhibited collagen-, U46619-, and AA-induced washed rabbit platelet aggregation in a concentration-dependent manner (Fig. 2) . These results were consistent with our previous data, and it seems that the antiplatelet effect of NQ12 was more sensitive in rabbit platelets than in human platelets (16) , which may be due to the difference of species.
Although platelets can be activated by a number of agonists, TXA 2 , an endogenous platelet agonist and vasoconstrictor, plays an important role in potentiation of platelet-rich thrombus formation (22) . It activates platelets by binding to a specific G-protein-coupled receptor linked to Gq and Gq 12 / 13 , which lead to intraplatelet calcium mobilization, activation of PKC, and myosin light-chain phosphorylation, respectively. TXA 2 is produced from arachidonate in platelets by the COX-TXA 2 synthase pathway (23, 24) . In the platelet aggregation assay (Fig. 2) , NQ12 inhibited both U46619-and AA-induced platelet aggregations in a concentrationdependent manner, indicating NQ12 may interfere with the TXA 2 synthesis or its action directly. Therefore, the effect of NQ12 on the generation of TXA 2 was first determined by using [
3 H]AA in intact rabbit platelets. As shown in Fig. 3 A and B , NQ12 concentration-dependently inhibited [
3 H]TXA 2 formation, while it failed to affect the production of [ 3 H]PGD 2 , a product simultaneously produced from AA via the COX pathway like TXA 2 , is indicating that NQ12 may selectively inhibit the activity of TXA 2 synthase rather than that of COX, which is also indirectly supported by the results that aspirin, a specific COX inhibitor, potently inhibits both TXA 2 and PGD 2 formations. It was also confirmed by a TXA 2 synthase activity assay that NQ12 suppressed the TXA 2 formation induced by PGH 2 , a precursor of the PGs and TXA 2 (Fig. 3D) .
Although it is theoretically rational that TXA 2 synthesis would inhibit platelet aggregation, it has been revealed that the course of TXA 2 synthase inhibition resulted in PGH 2 accumulation, which can interact with TXA 2 / PGH 2 receptors and consequently induce platelet activation. Therefore, we suggest that in addition to the inhibitory effect on TXA 2 synthase, NQ12 may also have a direct antagonistic effect on TXA 2 / PGH 2 receptors, as NQ12 potently and concentration-dependently inhibited the platelet aggregation induced by U46619, a TXA 2 receptor agonist. In fact, NQ12 did exhibit an antagonistic effect on U46619-induced platelet aggregation, possibly in a competitive manner (Fig. 4) . Further evaluation whether NQ12 has a direct effect on TXA 2 receptor is now in preparation. The present results well explain the in vivo antithrombotic effect of NQ12 on murine pulmonary thrombosis (16) , the lethal effect of collagen plus epinephrine that is caused by massive occlusion of the microcirculation of the lung by platelet thromboembolism or by vasoconstriction due to the increase of TXA 2 and PGF 2α from platelets. It has been reported that several drugs possessing TXA 2 synthase inhibitory effect also exhibited antagonistic effect on U46616-induced platelet aggregation (25 -27) , and our results are in agreement with the report that NQ-Y15, a 1,4-naphthoquinone derivative, exhibited a potent inhibitory effect on TXA 2 synthase and TXA 2 receptors (20) .
Since the intracellular concentration of free AA is low, agonists-mediated AA liberation is thought to be the rate-limiting step in the formation of PGs and other eicosanoids, including TXA 2 . To determine if NQ12 has any effect on AA liberation, the [ 3 H]AA-incorporated platelets were stimulated with collagen in the presence and absence of NQ12. As shown in Fig. 5A , NQ12 concentration-dependently inhibited collagen-induced AA liberation in a concentration-dependent manner. In addition, [ 3 H]DAG formations in collagen-stimulated [ 3 H]AA-prelabeled rabbit platelets were also inhibited by NQ12, indicating the suppressing effect of NQ12 on PLC (Fig. 5B) , which is in line with our previous finding that NQ12 exhibited a potent inhibitory effect on phospholipid breakdown (16) . Since collagen-mediated PLC activation can induce TXA 2 formation via free AA release by diglyceride lipase or by endogenous cPLA 2 from membrane phospholipids (28, 29) , the cPLA 2 activity assay was further employed. As shown in Fig. 5B , NQ12 has no effect on cPLA 2 activity. The present results also correlated well with the report by Chang et al. that NQ-Y15, a 1,4-naphthoquinone derivative, had no effect on PLA 2 activity (20) . Thus, it seems that the inhibitory effect of NQ12 on AA liberation from membrane phospholipid may be due to a prior inhibition of PLC, which resulted in the sequential inhibition of calcium increase, diglyceride lipase formation, and translocation of cPLA 2 from the cytoplasm to the membrane, thus leading to the final inhibition of AA liberation (21) .
In the cascade of AA metabolism in platelets, in addition to the COX pathway, there also exists a 12-LOX pathway, by which 12-HETE is produced. As shown in Fig. 3C , NQ12 also concentration-dependently inhibited AA-mediated 12-HETE production in platelets. Although a direct inhibitory effect of NQ12 on 12-LOX can not be ruled out, it seems that this effect may be due to a prior inhibition of phospholipid breakdowncalcium increase by NQ12 because it has been reported that in the case of 12-LOX, the enzyme translocation and 12-HETE production were dependent on the calcium concentration in platelets (30) .
Taken together, these results suggest that NQ12 has a potential to inhibit TXA 2 synthase activity with TXA 2 / PGH 2 receptor blockade and modulate AA liberation as well as 12-HETE formation in platelets. This may also be a convincing mechanism for the antithrombotic action of NQ12.
